1-3 of 3
Gavin S. Choy, PharmD, MBA
Close
Sort by
Journal Articles

Final Results of Anagrelide Controlled-Release (GALE-401) Safety, Efficacy and Pharmacokinetics in Subjects with Myeloproliferative Neoplasms (MPN)-Related Thrombocytosis

Phu V. Troung, MD F.A.C.P., Marc Saltzman, MD, Alberto Bessudo, MD, William Jawien, MD, Roger M. Lyons, MD F.A.C.P., Dmitriy Berenzon, MD, Raul Mena, MD, Nasiema Wingate-Pearse, Olivier Barriere, PhD, Hali E. Beeson, Paul F. Glidden, PhD, Gavin S. Choy, PharmD, MBA, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4074.
https://doi.org/10.1182/blood.V126.23.4074.4074
Published: 2015
Journal Articles

Targeting Pim Kinase Activity with the Novel Small Molecule Inhibitor SGI-1776 Significantly Augments the Efficacy of Cytarabine In Models of Acute Myeloid Leukemia

Kevin R Kelly, MD, Kelli Oberheu, B.S., Ernest Medina, B.S., Claudia M Espitia, MS, Devalingam Mahalingam, MD, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Steffan T Nawrocki, PhD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S Carew, PhD
Journal: Blood
Blood (2010) 116 (21): 3253.
https://doi.org/10.1182/blood.V116.21.3253.3253
Published: 2010
Journal Articles

SGI-110, a Novel Second Generation Potent DNA Methylation Inhibitor, In Development for the Treatment of MDS and AML. Preclinical Safety, Pharmacokinetics, and DNA Methylation Results of a Low Volume Subcutaneous (SC) Formulation

Jason Scholl, PhD, Rajashree Joshi-Hangal, PhD, Roger Inloes, PhD, Chongtie Shi, PhD, Pietro Taverna, PhD, Gavin S. Choy, PharmD, MBA, Sanjeev Redkar, PhD, Mohammad Azab, MD, MSC, MBA
Journal: Blood
Blood (2010) 116 (21): 1872.
https://doi.org/10.1182/blood.V116.21.1872.1872
Published: 2010